Amyotrophic Lateral Sclerosis
A progressive motor neuron disease. Research has identified microbiome changes in ALS patients. Data is limited, but shared mechanisms of neuroinflammation make microbiome-targeted therapy a promising direction.
What Is ALS?
Amyotrophic lateral sclerosis (Lou Gehrig's disease) is a neurodegenerative disease that affects upper and lower motor neurons.
About the Disease
ALS affects approximately 2-3 people per 100,000. The average age of onset is 55-65 years. 90% of cases are sporadic, 10% are familial forms.
New Data: Patients with ALS have been found to have characteristic gut microbiome changes associated with disease progression. Neuroinflammation is a common mechanism through which the microbiome may influence the course of ALS.
Symptoms
- Progressive muscle weakness
- Limb muscle atrophy
- Speech and swallowing difficulties
- Fasciculations (muscle twitching)
- Respiratory failure in late stages
The Gut-ALS Connection
- Altered microbiome composition in ALS
- Increased intestinal permeability
- Neuroinflammation and systemic inflammation
- Reduced neuroprotective metabolites
Conventional Treatment
Riluzole and edaravone are the only approved drugs. They slow progression by a few months.
ALS remains an incurable disease. The search for new therapeutic approaches is critically important.
Why Fecal Microbiota Transplantation (FMT) for ALS?
Research shows a link between the microbiome and ALS progression. Modulation of gut flora may have a neuroprotective effect. Data is still limited -- we are transparent about this.
Dysbiosis in ALS
Microbiome changes, decreased Akkermansia
Neuroinflammation
Microglial activation, neuronal damage
FMT Transplantation
Restoration of neuroprotective flora
Potential Effect
Slowing of progression (under investigation)
Scientific Rationale
Studies in mice with an ALS model showed that certain gut bacteria (Akkermansia muciniphila) can slow disease progression through nicotinamide production. However, clinical data in humans remains limited.
Potential Mechanisms
- Reduction of neuroinflammation
- Restoration of intestinal barrier function
- Increased neuroprotective metabolites
- Modulation of the immune response
Important: FMT for ALS is at an experimental stage. Clinical data in humans is limited to isolated case reports. We transparently inform patients about the level of evidence.
Research Results
FMT research for ALS is at a very early stage, but preclinical data is encouraging.
Early
Experimental stage
SOD1
Mouse models studied
Case
Individual clinical cases
Akkermansia
Key neuroprotective bacterium
Key Studies
- Blacher et al., Nature 2019: Akkermansia muciniphila slowed ALS progression in mice through nicotinamide production
- Mazzini et al., 2018: Characteristic microbiome changes identified in ALS patients
- Clinical cases 2020-2024: Isolated reports of condition stabilization following FMT
Free consultation · We respond within 24 hours
Hope for the Future
New approaches to ALS treatment
"The discovery of the gut microbiome's role in ALS progression has been one of the important breakthroughs in understanding this disease. Akkermansia muciniphila showed the ability to slow neurodegeneration in experiments. Microbiome-targeted therapy may become a complement to existing treatment methods."
ALS Researchers
Weizmann Institute of Science
Related Conditions
FMT is also being studied for other neurodegenerative diseases
Autism (ASD)
Developmental disorder with communication and behavioral features
Parkinson's
Neurodegenerative disease with motor impairment
Alzheimer's
Progressive memory and cognitive impairment
Depression
Mood disorder with persistent emotional decline
Related Articles
Looking for New Options?
If you or a loved one has ALS, contact us via Telegram or WhatsApp. We will share information about current research and honestly assess the available options.
Free consultation · We respond within 24 hours
China, Jiangxi Province, Shangrao City, Guangxin District, West Binjiang Road